|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||44.05 - 44.76|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.75|
Verscend Technologies, Inc. (“Verscend”), a portfolio company of Veritas Capital (“Veritas”) and a leader in data-driven healthcare solutions, has completed its acquisition of Cotiviti Holdings, Inc. (“Cotiviti”), a leading provider of payment accuracy and analytics-driven solutions focused primarily on the healthcare industry. Emad Rizk, M.D., current president and chief executive officer of Verscend, will retain these titles for the combined business.
Cotiviti Holdings, Inc. (COTV) (“Cotiviti”), a leading provider of payment accuracy and analytics-driven solutions focused primarily on the healthcare industry, and Verscend Technologies, Inc. (“Verscend”), a portfolio company of Veritas Capital (“Veritas”) and a leader in data-driven healthcare solutions, announced today that Cotiviti’s shareholders voted to approve the proposed merger of Cotiviti with a subsidiary of Verscend at a special meeting of Cotiviti’s shareholders held August 24, 2018. The final results will be available in a current report on Form 8-K, which Cotiviti expects to file with the Securities and Exchange Commission within four business days. Upon closing of the merger, Cotiviti’s shareholders will be entitled to receive $44.75 in cash per share of Cotiviti common stock (without interest and subject to any applicable withholding taxes or other amounts required to be withheld therefrom under applicable law), and Verscend will assume all of Cotiviti’s outstanding debt, resulting in an enterprise value of approximately $4.9 billion.
NOTE: On August 09, 2018, the press release was corrected as follows: The first line under Assignments in the debt list was changed to Senior secured revolving credit facility and first-lien term loan, due 2023 and 2025, Assigned B3 (LGD3). New York, August 06, 2018 -- Moody's Investors Service ("Moody's") affirmed healthcare-data-analytics-services provider Verscend Holding Corp.'s ("Verscend") B3 Corporate Family Rating ("CFR") and its B3-PD Probability of Default Rating ("PDR") after its announcement that it will be acquiring Cotiviti Holdings, Inc. ("Cotiviti"). Moody's also assigned B3 ratings to the company's new first-lien senior secured credit facilities, including a $300 million revolver and $3,165 million term loan, and assigned Caa2 ratings to $1,150 million of new senior unsecured notes.
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York ...
The securities litigation law firm of Brower Piven, A Professional Corporation, notifies investors that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of all common stockholders of Cotiviti Holdings, Inc. (COTV) (“Cotiviti” or the “Company”) opposing the proposed acquisition of Cotiviti by Veritas Capital. The complaint seeks relief on behalf of the named plaintiff and all other similarly situated shareholders of Cotiviti and asserts that the Company’s Board of Directors breached their fiduciary duties by failing to disclose certain material information that is necessary for shareholders to properly assess the fairness of the proposed merger.
NEW YORK , Aug. 2, 2018 /PRNewswire/ -- Ankers Biosciences, Inc. (AKER) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations of improper recognition ...
BALA CYNWYD, PA / ACCESSWIRE / July 27, 2018 / Law office of Brodsky & Smith, LLC announces that it is continuing its investigation of potential claims against the Board of Directors of Cotiviti Holdings, Inc. ("Cotiviti" or "the Company") (NYSE:COTV News) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Veritas Capital ("Vertias"). Under the terms of the transaction, Cotiviti shareholders will receive only $44.75 in cash for each share of Cotiviti stock they own. The investigation concerns whether the Board of Cotiviti breached their fiduciary duties to shareholders and whether Veritas is underpaying for the Company.
Cotiviti Holdings, Inc. (COTV) delivered earnings and revenue surprises of 4.55% and -3.29%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK , July 16, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York ...
KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (firstname.lastname@example.org) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-cotv/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.